LONDON, Dec. 21,
2023 /PRNewswire/ -- Virax Biolabs Group Limited
(NASDAQ: VRAX) ("Virax" or the "Company"), an innovative
biotechnology company focused on the detection of immune responses
and diagnosis of viral diseases, today announced a strategic
collaboration with the University of Manchester and the Northern Care Alliance
Foundation Trust, who have a track record in working together to
deliver translational immunology research for respiratory
viral infections. This collaboration aims to apply the ViraxImmune
IVD platform to broaden the understanding of T-Cell immune response
in COVID patients in the ImRESP (Immunology of Respiratory
Conditions) study.
As part of the ImRESP clinical study, the ViraxImmune T-Cell
assay will be assessed in respiratory disease patients where the
role of memory T-cell driven immunity will be
evaluated. Furthermore, within the ImRESP clinical
study, the T-cell assay will be assessed in a distinct cohort of
patients experiencing Long COVID symptoms. This segment of the
study will involve the longitudinal assessment of samples, aiming
to discern specific phenotypic T-cell profiles associated with
these individuals.
"Our valued research collaboration with University of
Manchester is instrumental in
generating impactful data on T-cell-driven immunity's role in
symptoms linked to T-cell exhaustion and chronic inflammation
following post-viral exposure", said James
Foster, CEO at Virax Biolabs, "The data generated as part of
this collaboration will be used in the ongoing development of our
In Vitro Diagnostic (IVD) test for Long COVID to help with the
early detection and treatment management of these individuals".
"Disordered inflammation is likely to be central issue for many
people diagnosed with long COVID. This study will help to identify
and characterize this subset of patients which is the first step
towards rationalizing future therapies," said Dr Sean Knight, Chief Investigator for the ImRESP
study.
This collaboration underscores Virax Biolabs' commitment to
advancing diagnostic capabilities and understanding immune
responses, particularly in post-viral syndromes and conditions
associated with chronic inflammation. The collaboration with the
University of Manchester
represents a significant step toward developing innovative
solutions for diagnosing and managing post-viral syndromes.
ImRESP is an observational study sponsored by the Northern Care
Alliance Foundation Trust in the UK and has been designed to
evaluate the long term effects of respiratory infections on the
immune system in many different contexts including long COVID and
progression of chronic lung disease.
About Virax Biolabs Group Limited.
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. In addition to distributing an array
of in-vitro diagnostic test kits, Virax Biolabs Group Limited is
currently developing T cell based test technologies with the
intention of providing an immunology profiling platform. T cell
testing can be particularly effective in the diagnosis and
therapeutics of Long COVid as well as chronic inflammation and
other post viral syndromes including myalgic encephalomyelitis,
Hepaitis B, Malaria, Herpes and Human Papillomavirus.
For more information, please
visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March
31, 2023. Although we believe the expectations reflected in
such forward-looking statements are reasonable, we can give no
assurance that such expectations will prove to be correct. We are
not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-forges-strategic-research-collaboration-with-university-of-manchester-and-the-northern-care-alliance-foundation-trust-to-enhance-understanding-of-immune-responses-in-covid-patients-302020681.html
SOURCE Virax Biolabs